why swiss- drug maker novartis fought to extend patents in india on its improved cancer-treatment gleevec. novartis claimed it had made the drug more effective and thus warrented a new patent. india's supreme court disagreed. the ruling allows indian companies to make copycat versions. "if the drug companies aren't able to have patent protection, maybe not in every country but in most countries, they're not going to be able to make back the sums on money it takes to develop drugs." pharmaceutical researchers and manufacturers of america, a trade group, says, "the indian courts have come down on the side that doesn't recognize the value of innovation and the value of strong intellectual property." however, analysts doubt the ruling will influence decisions beyond india, nor do they think it will affect the overall profitability of large pharmaceutical companies. "overall, we still think the pharmaceutical fundamentals look quite good. from a valuation standpoint, a lot of stocks have run quite a bit, and there aren't a lot that we think are extremely undervalued." nonetheless, novartis cla